Background-Cystatin C (CyC) is more sensitive than serum creatinine (sCr) to rapidly detect acute changes in renal function. Methods and Results-We measured CyC together with sCr in 410 consecutive patients with chronic kidney disease undergoing either coronary and/or peripheral angiography and/or angioplasty. sCr was assessed at baseline and 24 and 48 hours after contrast media exposure. CyC was assessed at baseline and at 24 hours. Major adverse events (including death of any cause and dialysis) at 12 months were assessed. At 48 hours after contrast media exposure, contrast-induced acute kidney injury (defined as a sCr increase Ն0.3 mg/dL) occurred in 34 patients (8.2%). A CyC increase concentration Ն10% at 24 hours after contrast media exposure was detected in 87 patients (21.2%). This was the best CyC cutoff for the early identification of patients at risk for contrast-induced acute kidney injury (negative predictive valueϭ100%; positive predictive valueϭ39.1%). According to the defined cutoffs (that is, increase in CyC Ն10% and sCr Ն0.3 mg/dL), major adverse events occurred in 16 of 297 patients (5.4%) without any cutoffs satisfied (group 1), in 9 of 49 patients (18.4%) with only a CyC increase Ն10% (group 2), and in 9 of 31 patients (29%) with both cutoffs satisfied (group 3). By logistic regression analysis, the independent predictors of major adverse events at 1 year were group 2 (odds ratioϭ2.52; 95% confidence interval, 1.17 to 5.41; Pϭ0.02), group 3 (odds ratioϭ4.45; 95% confidence interval, 1.72 to 11.54; Pϭ0.002), and baseline glomerular filtration rate (odds ratioϭ0.91; 95% confidence interval, 0.88 to 0.95; PϽ0.001). Conclusions-In patients with chronic kidney disease, CyC seems to be a reliable marker for the early diagnosis and prognosis of contrast-induced acute kidney injury. (Circulation. 2010;121:2117-2122.)
ated with a prolonged in-hospital stay and represents a powerful predictor of unfavorable early and late outcome. 1, 2 Therefore, it has been recommended to monitor renal function in all patients at risk with serial measurements of serum creatinine (sCr) after contrast media (CM) exposure. 2, 3 However, the delayed increase in sCr is a potential reason for overlooking CI-AKI 4, 5 and, on the contrary, for prolonging hospital stay in the vast majority of patients who will not develop CI-AKI.
Clinical Perspective on p 2122
Cystatin C (CyC) is more sensitive than sCr to rapidly detect acute changes in renal function. 6, 7 Preliminary data suggest that the increase of CyC achieves a maximum within 24 hours after CM exposure. 8, 9 However, limited data exist on whether changes in CyC are superior to sCr in predicting future major adverse events (MAE). 10 Hence, we performed a prospective study comparing changes in sCr and CyC in patients at medium to high risk for CI-AKI undergoing CM administration during coronary or peripheral procedures. The purpose was to assess whether changes in serum CyC at 24 hours after CM exposure are a reliable index (1) for an early diagnosis of CI-AKI and (2) in predicting future MAE.
Methods

Patient Population
From January 2007 to September 2009, we considered all consecutive patients with chronic kidney disease (than is, with an estimated glomerular filtration rate [eGFR] Ͻ60 mL/min per 1.73 m 2 ) scheduled for coronary and/or peripheral angiography and/or angioplasty procedure. eGFR was calculated by applying the Levey modification of the Modification of Diet in Renal Disease formula: (186.3ϫserum creatinine Ϫ1.154 )ϫ(age Ϫ0.203 )ϫ(0.742 if female). 11 Exclusion criteria were preexisting dialysis, multiple myeloma, pulmonary edema, acute myocardial infarction, recent (Յ2 days) exposure to CM, pregnancy, and administration of theophylline, dopamine, mannitol, or fenoldopam. The local ethics committee approved the study, and all patients gave written informed consent.
All patients were treated by intravenous sodium bicarbonate plus N-acetylcysteine before and after administration of the CM. 12 Sodium bicarbonate (154 mEq/L in dextrose and H 2 O) infusion was started at least 1 hour before the procedure and lasted 6 hours after administration of the CM. 13 N-Acetylcysteine (Fluimucil, Zambon Group SpA, Milan, Italy) was administered orally at a dose of 1200 mg twice daily on the day before and on the day of CM exposure. 12 Diuretics were routinely withheld on the day of the procedure. The risk score for predicting CI-AKI was calculated according to the following algorithm: hypotension (integer score 5), intra-aortic balloon pump support (integer score 5), congestive heart failure (integer score 4), age Ͼ75 years (integer score 4), diabetes mellitus (integer score 3), eGFR Ͻ60 (integer score 2 to 6), preexisting anemia (integer score 3), and CM volume (integer score 1 for each 100 mL). The global scores Յ5, 6 to 10, 11 to 16, and Ն16 anticipate a CI-AKI risk of 7.5%, 14%, 26.1%, and 57.3%, respectively. 14 Iodixanol (Visipaque, 320 mg iodine/mL, Amersham Health), a nonionic, iso-osmolality (290 mOsm/kg water) CM, was used in all patients.
sCr, serum sodium, and serum potassium were measured 24 hours before and 24 and 48 hours after administration of the CM; additional measurements were performed in all cases of impairment of renal function. Serum CyC was measured 24 hours before and 24 hours after administration of the CM with the use of the Dade Behring N Latex Cystatin C assay (Dade Behring Diagnostics, Marburg, Germany). 15 
Study Purpose
The primary purposes of the study were to assess whether changes in CyC levels at 24 hours after CM exposure (1) anticipate the occurrence of CI-AKI, defined as an increase in sCr concentration of Ն0.3 mg/dL from the baseline value at 48 hours after administration of the CM or the need for dialysis, 16 and (2) predict the occurrence of 12-month MAE, defined as death from any cause and further deterioration of renal function requiring chronic dialysis. Clinical follow-up was performed by a visit at the outpatient clinic or by a telephone interview with the patients or their relatives at 1, 6, and 12 months. For any reported event, all available medical records (ie, case records, dialysis schedules, death certificates) were obtained and reviewed by 2 independent and blinded adjudicators.
Statistical Analysis
Continuous variables are given as meanϮ1 SD or median and interquartile ranges, when appropriate. The Student t test and 
Results
Clinical and Biochemical Characteristics
Four hundred ten consecutive patients with chronic kidney disease were included in the study. The clinical and biochemical characteristics of the patients are shown in Tables 1 and 2 
Creatinine Kinetic
Median sCr concentration significantly decreased from baseline to 24 hours after CM administration (PϽ0.001) but was unchanged at 48 hours (Pϭ0.30) ( Table 2 ). An increase of sCr concentration Ն0.3 mg/dL from baseline value occurred in 16 patients (3.9%) at 24 hours and in 34 patients (8.2%) at 48 hours after CM administration. The distribution of changes in sCr according to a 0.3-mg/dL increase or decrease is summarized in the Table 3 .
CyC Kinetic
Median serum CyC concentration did not significantly change from baseline to 24 hours after CM administration (PϽ0.38) ( Table 2) . At 24 hours, we observed the following changes: (1) any increase above the upper limit of normal in 165 patients (40.2%); (2) an absolute increase Ն0.3 mg/dL in 31 patients (7.5%); (3) a Ն10% increase in 87 patients (21.2%); (4) a Ն15% increase in 52 patients (12.7%); and (5) a Ն25% increase in 16 patients (3.9%).
The relationships between changes of CyC levels and CI-AKI, defined by a sCr increase Ն0.3 mg/dL, are represented in Table 4 . A CyC increase Ն10% at 24 hours after administration of the CM was the best increment cutoff value for the early identification of patients at risk for CI-AKI. The distribution of the changes in CyC according to a 10% increase or decrease is depicted in Table 3 . By receiver operating characteristic analysis, we found that a CyC increase Ն10% at 24 hours had a 100% sensitivity and a 85.9% specificity for predicting a sCr increase Ն0.3 mg/dL ( Figure  1 ). The negative predictive value was 100%; indeed, none of the 323 patients with CyC increase Ͻ10% at 24 hours after administration of the CM had a sCr increase Ն0.3 mg/dL. On the contrary, the positive predictive value of CyC increase Ն10% was 39.1%; indeed, the majority of patients with a CyC increase Ն10% at 24 hours did not eventually develop a sCr increase Ն0.3 mg/dL.
Long-Term Outcome
One-year outcome was available in 377 patients (92%). Globally, MAE occurred in 34 patients (9.0%). In particular, death occurred in 26 patients (6.9%) and chronic dialysis in 8 patients (2.1%). MAE occurred in 16 of 297 patients (5.4%) in group 1 (that is, a CyC Ͻ10% and sCr increase Ͻ0.3 mg/dL), in 9 of 49 patients (18.4%) in group 2 (that is, a CyC Ն10% and sCr increase Ͻ0.3 mg/dL) (unadjusted odds ratio (Figure 2 ). By logistic regression analysis, the independent predictors of MAE at 1 year were a CyC Ն10% alone (as shown in group 2) (ORϭ2.52; 95% CI, 1.17 to 5.41; Pϭ0.02) and associated with a sCr increase Ն0.3 mg/dL (as shown in group 3) (ORϭ4.45; 95% CI, 1.72 to 11.54; Pϭ0.002) and baseline eGFR (ORϭ0.91; 95% CI, 0.88 to 0.95; PϽ0.001) ( Table 5 ).
Discussion
The main results of the present study are that serum CyC seems to be a reliable marker (1) for an early (24-hour) diagnosis of CI-AKI and (2) for predicting the occurrence of MAE at follow-up in patients with chronic kidney disease undergoing CM exposure.
sCr as a Marker of CI-AKI
Although in 80% of CI-AKI cases, sCr starts rising within the first 24 hours after CM exposure, 17 the sCr typically peaks 2 to 5 days after CM and returns to baseline or near baseline within 1 to 3 weeks. 2, 3 Therefore, in all patients at risk, a follow-up sCr should be obtained at 48 to 72 hours after CM exposure. [2] [3] [4] 18 This implies an intrinsic delay of treatment of patients who will develop CI-AKI and, on the contrary, a prolonged hospital stay in patients who will not develop CI-AKI. Furthermore, creatinine suffers from 2 significant limitations. 4 First, creatinine excreted in the urine is not solely a result of glomerular filtration but also of renal tubular secretion. 19 This means that changes in sCr will underestimate the true fall in GFR. Second, after an acute fall in GFR, less creatinine is excreted. The retained creatinine is distributed in total body water. Thus, the serum level can be expected to rise slowly and will continue to rise until a new steady state has occurred. Therefore, although the injury induced by CM impairs GFR almost immediately, it requires 24 to 48 hours for the fall in GFR to be reflected in an elevated level of sCr.
Serum CyC as a Marker of CI-AKI
CyC is a 122-amino acid, nonglycosylated protein that is a member of the family of cysteine proteinase inhibitors. 20 It is produced at a constant rate by all nucleated cells, representing in the true sense of the word a "housekeeping gene product." CyC concentration is independent of age, sex, changes of muscle mass, and nutrition. CyC levels are lower in the hypothyroid and higher in the hyperthyroid state compared with the euthyroid state. 21 It is found in relatively high concentrations in many body fluids, and its low molecular weight (13.3 kDa) and positive charge at physiological pH levels facilitate its glomerular filtration. It is later reabsorbed and almost completely catabolized in the proximal renal tubule. 22 Because of its constant rate of production, its serum concentration is therefore determined by glomerular filtration. Indeed, CyC does not undergo tubular secretion and appears in the urine solely through filtration. 6, 23 For these reasons, CyC has the potential to be a useful marker in detecting both chronic and acute changes in GFR. 24 -26 The shorter (1.5-hour) half-life of CyC compared with creatinine accounts for the more rapid rise and the earlier attainment of a new steady state. 27 CyC is distributed in the extracellular volume, 28 whereas sCr is distributed in the total body water, 29 a volume that is 3 times larger. Therefore, the half-life of creatinine compared with CyC will be 3 times longer, and the time to achieve a new steady state will increase proportionally, implying that sCr will rise more slowly. In the present study, we observed that (1) a CyC increase Ͻ10% at 24 hours is a reliable marker for ruling out CI-AKI and (2) a CyC increase Ն10% at 24 hours is an independent predictor of 1-year MAE. The first observation may allow physicians an earlier discharge of the majority (Ͼ80%) of patients, thus avoiding an unnecessary prolonged hospitalization with associated practical and economic advantages. 30 The second observation identifies a subgroup of patients at higher risk for future MAE. 10, 31, 32 This observation may be explained by 2 reasons. First, CyC seems to be a better measure of kidney function than sCr and eGFR. 6, 7, 30 Second, CyC may provide prognostic information beyond its role as an index of kidney function and also may be a better overall measure of the spectrum of pathophysiological abnormalities that accompany kidney disease. CyC seems to be a potential predictor of the presence or development of cardiac structural abnormalities. 33 Indeed, the Dallas Heart Study showed that CyC is independently associated with left ventricular mass, concentricity, and wall thickness. 34 Some studies have also found a relationship between CyC and C-reactive protein 35 and inducible myocardial ischemia. 36 
Study Limitations
CyC levels have been assessed only at 24 hours, and therefore its trajectory cannot be defined. We chose to control the CyC level at 24 hours because elective patients are usually discharged the day after the procedure. We cannot exclude the possibility that an earlier rise (within hours) may occur. Further studies are necessary to test whether an early CyC rise (ie, at 6 or 12 hours) may be diagnostic. CyC is a sensitive marker of reduction in GFR and not a marker of kidney injury. Other biomarkers (such as kidney injury molecule 1, neutrophilin gelatinase-associated lipocalin, and interleukin-18) identify tubular injury and have been shown to rise much more quickly in response to acute kidney injury (hours instead of days). 37 However, these markers of injury have not been validated as predictors of long-term outcome.
In conclusion, the assessment of CyC at 24 hours after CM exposure allows an early diagnosis of CI-AKI and predicts the occurrence of future MAE. Although more expensive than sCr, measurement of CyC should be adopted not only as a diagnostic test for kidney function but, more importantly, as a prognostic tool for future MAE among patients with chronic kidney disease undergoing CM exposure. Variables entered into the model were diabetes mellitus, baseline eGFR, left ventricular ejection fraction, and groups (defined according to the presence or not of sCr increase Ն0.3 mg/dL and CyC increase Ն10%).
